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Available online 4 September 2016Background: Despite the high incidence and mortality of ST-segment elevation myocardial infarction (STEMI)
among the very elderly, riskmarkers for this condition remain poorly deﬁned. This studywas designed to identify
independent markers of STEMI among individuals carefully selected for being healthy or manifesting STEMI in
b24 h.
Methods:We enrolled participants aged 80 years or older of whom 50 were STEMI patients and 207 had never
manifested cardiovascular diseases. Blood tests, medical and psychological evaluations were obtained at study
admission. Odds Ratio (OR) and attributed risk (AR) were obtained by multivariate regression models using
STEMI as dependent variable.
Results: Low glomerular ﬁltration rate (GFR) [OR:4.41 (1.78–10.95); p = 0.001], reduced levels of HDL-C
[OR:10.70 (3.88–29.46); p = 0.001], male gender [OR:12.08 (5.82–25.08); p = 0.001], moderate to severe
depressive symptoms [OR:10.00 (2.82–35.50); p = 0.001], prior smoking [OR:2.00 (1.05–3.80); p = 0.034]
and current smoking [OR:6.58 (1.99–21.70); p=0.002] were signiﬁcantly associatedwith STEMI. No association
was found between STEMI and age, diabetes, hypertension, mild depressive symptoms, triglyceride or LDL-C.
Conclusions: This is the ﬁrst case–control study carried out with very elderlies to assess STEMI risk. Our ﬁndings
indicate that reducedHDL-C, GFR,male gender, smoking habits andmoderate to severe depressive symptoms are
markers of STEMI in this age group.
General Signiﬁcance: In Individuals aged 80 ormore years, a greater attentionmust be paid to lowHDL-C and GFR
at the expense of conventional STEMI risk factors for younger adults such as diabetes mellitus, hypertension and
high LDL-C or triglyceride.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The 20th century wasmarked by a 300% increase in the elder popula-
tion in developed countries [1]. Impressively, another similar increase is
expected to take place in half of that time in the present century [2]. In-segment elevation myocardial
tion; CK-MB,MB fraction of cre-
, BeckDepression Inventory ver-
emoglobin; SBP, systolic blood
iamine tetraacetic acid; CRP, C-
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ard deviation; IQR, interquartile
, attributable risk.
and Vascular Biology (AteroLab),
amp), 13084-971, Campinas, SP,
o).
. This is an open access article underdeveloping countries such as China, Brazil, and Colombia, the growth
of the aged population is occurring 3-times faster as compared with
developed countries [3]. As one might expect, such rapid growth in
longevity has generated a new demographic proﬁle in which there
is a larger proportion of individuals 80 years or more.
It is well known that both the incidence and mortality from cardio-
vascular disease (CVD) in the elderly rises with age [4]. Indeed, the
mortality rate after ST-segment elevation myocardial infarction (STEMI)
in these individuals is 10-fold higher than in those with 65 years or less
[5]. These ﬁgures are probably underestimated, considering the difﬁculty
of access to emergency units due to walking difﬁculties or cognitive
dysfunction commonly found among these individuals.
Although primary prevention would certainly be the best strategy
for reducingmorbidity andmortality related to STEMI, there is currently
insufﬁcient data to identify risk predictors in this speciﬁc population of
patients. In addition, the combined effect of the enhanced incidence andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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association with traditional risk factors and potentially hinder the
identiﬁcation of new ones. In this context, we compared two cohorts
of very elderly individuals (≥80 years) who are healthy or in the ﬁrst
hours after STEMI in order to identify independent risk markers.
2. Material and methods
2.1. Study design and participants
For the present study, cases and controls were selected in a one-to-
four ratio matching for age based on two studies databases. Only
patients 80 years or older from the Brasília Heart Study (BHS) database
were selected for analysis (n=50). BHS is a prospective ongoing obser-
vational cohort enrolling STEMI patients admitted at the Hospital de
Base do Distrito Federal (Brasília, Brazil) since 2006. BHS inclusion
criteria was: (i) b24 h after onset of MI symptoms, (ii) ST-segment
elevation of at least 1 mm (frontal plane) or 2 mm (horizontal plane)
in 2 contiguous leads and (iii) increased myocardial necrosis markers
above reference limit of CK-MB (25 U/L) and troponin (0.04 ng/mL)
followed by a decline of both markers. Exclusion criteria were
(i) cognitive impairment, (ii) inability to attend follow-up and (iii)
other comorbidities that lead to signiﬁcantly shorter life expectancy.
BHS is registered at ClinicalTrials.org (NCT02062554) [6].
The control group was composed of individuals consecutively
enrolled in the Brasília Study on Healthy Aging (BSHA) (n = 207).
BSHA is a prospective cohort of healthy very elderly individuals (80 to
102 years) who voluntarily accepted to participate and were followed
at the outpatient clinic of the Biocardios Institute of Cardiology (Brasília,
Brazil) since 2008. Exclusion criteriawere (i)manifested atherosclerotic
disease (MI, stroke, or peripheral arterial disease) as indicated by a
medical evaluation, electrocardiogram or echocardiogram, (ii) functional
dependence or institutionalization, (iii) cognitive impairment assessed
by mini-mental state examination (b13 points), (iv) use of any anti-
inﬂammatory drugs in the last 30 days, (v) current or previous diagnosis
of neoplastic or immune inﬂammatory disease, (vi) chronic obstructive
pulmonary disease, (vii) glomerular ﬁltration rate b 25 mL/min/1.73 m2,
(viii) hepatic disease (aspartate or alanine transaminases ≥1.5 upper
reference limit), (ix) chronic infectious disease (≥3 months), (x) left
ventricle ejection fraction b50% on echocardiography and (xi) neoplastic
disease at admission or until the ﬁrst year after enrollment. Neoplastic
disease was investigated through evaluation of fecal occult blood,
mammography and clinical breast exam, prostate-speciﬁc antigen plasma
assay, digital rectal examination and Papanicolaou smear analysis accord-
ing to current guidelines [7]. BSHA is registered at ClinicalTrials.gov
(NCT02366104) [8].
Both studies were carried out in accordance with The Declaration of
Helsinki [9], and were approved by the local Ethics Committee (BHS:
083/06 and BSHA: 213/08). Informed consent was obtained from all
individual participants included in the study.
2.2. Clinical and psychological evaluation
All participants underwent a structured detailed clinical question-
naire, anthropometric measurements, blood collection and psychological
tests. Depressive symptoms manifested in the last weeks before STEMI
(BHS study) or before the admission into the BSHA study were evaluated
by the use of Beck Depression Inventory version II (BDI-II) or Geriatric
Depression Scale (GDS), respectively. These two self-reported inventories
were validated in this age group and have shown to be highly correlated
[10]. Ex smoking status was deﬁned as smoking cessation for at least
6 months. Diabetes was deﬁned as the use of anti-diabetic medications,
fasting glycaemia ≥126 mg/dL or glycated hemoglobin (HbA1c) ≥6.5%.
Hypertension was deﬁned by the use of antihypertensive drugs or by
the systolic blood pressure (SBP) ≥140mmHg or diastolic blood pressure
(DBP) ≥90 mm Hg.2.3. Biochemical analysis
AmongSTEMI patients, blood sampleswere obtained in theﬁrst 24h
from MI symptoms in order to avoid the reported lipid proﬁle changes
that occur after this time window [11]. Among controls, blood samples
were obtained at admission. Blood sampleswith EDTAwere centrifuged
after collection at 5 °C and at 4500 rpm for 15min to separate plasma and
cells. Biochemical analyses were performed in duplicates. An automatic
chemical analyzer was used to do the following analysis: C-reactive pro-
tein (CRP; high-sensitivity assay, Cardiophase, Dade Behring, Marburg,
Germany), total cholesterol (CHOD-PAP, Roche Diagnostics, Mannheim,
USA), high-density lipoprotein cholesterol (HDL-C, Roche Diagnostics,
Mannheim, USA), triglycerides (GPO-PAP, Roche Diagnostics, Mannheim,
USA), urea and creatinine (GLDH, Hitachi, Tokyo, Japan). Low-density
lipoprotein cholesterol (LDL-C) was calculated using the Friedewald
formula. Glomerular ﬁltration rate (GFR) was estimated by abbreviated
MDRD equation: Estimated GFR (mL/min/1.73 m2) = 186 × (creati-
(creatinine/88.4)−1.154 × (age) −0.203 × (0.742, if female) × (1.210, if
black) [12].
2.4. Statistical analysis
Normal data are presented asmean± SD and skewed data asmedian
and interquartile range (IQR). Categorical and continuous baseline data
were tested using chi-square and t-Student tests, respectively. Analyses
of covariance (ANCOVA) with adjustments for gender and age were per-
formed for comparison ofmean change from the baseline. Assumptions of
the ANCOVA models (linearity, normality of distribution and equal
variance) were checked using histograms, normal probability plots and
residual scatter plots. Ordinal logistic regression analyses were used to
assess the association between the presence of STEMI and the following
continuous variables categorized into tertiles: age, LDL-C, HDL-C, triglyc-
eride levels and GFR. Binary logistic regression was used to assess the
association between STEMI and categorical binary data: gender, diabetes
mellitus, hypertension, depressive symptoms, and current/ex smoking.
Odds ratios (OR) for STEMI are reported across individual risk factors in
unadjusted and fully adjusted models. For all multivariable procedures,
variables that displayed a p-value b0.05 in univariate analyses were
selected as covariable. Attributable Risk (AR) was used to estimate the
impact of each risk marker of STEMI in the very elderly. Statistical
analysis was performed using SPSS®, version 21 for Mac (IBM) and
SAS Analytics®, version U forMac (SAS Institute Inc.) for AR. Probability
value of b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Clinical and laboratorial characteristics
Clinical and laboratorial baseline characteristics of study participants
are in Table 1. Higher frequency of female gender and higher levels of
HDL-C and GFR were found in controls. Moderate to severe depressive
symptoms, prior and current smoking were more frequently found in
cases. Controls had quit smoking for longer than cases (32 ± 17 vs.
20 ± 12 years; p= 0.027).
3.2. STEMI risk markers
Table 2 shows all individual categorical risk markers in unadjusted
analysis (Model 1) and after fully adjustment (Model 2). In order to
avoid over-ﬁtting, prior and current smoking statuswere pooled together
as smoking. Based on the univariate analysis, selected covariates for
adjustments were: gender, depressive symptoms, smoking, GFR, and
HDL-C.
Although the age of participant ranged between N2 decades, it was
not related to STEMI occurrence. In contrast, reduced levels of GFR or
HDL-C were associated with STEMI in both unadjusted and fully
Table 1
Baseline characteristics of clinical and laboratory data of participants.
Characteristics Controls
n= 207
Cases
n= 50
p-Value ANCOVA
p-valuea
Age, (years) 83 (6) 84 (8) 0.257 –
Gender: female, % (n) 79 (164) 24 (12) b0.001 –
Depressive symptoms, % (n) 22 (31) 32 (13) 0.001 0.001
Mild 16 (27) 12 (5) 0.884 0.895
Moderate to severe 2 (4) 20 (8) b0.001 0.001
Diabetes mellitus, % (n) 23 (48) 16 (8) 0.341 0.449
Hypertension, % (n) 77 (159) 68 (34) 0.205 0.981
Current smoking, % (n) 2 (5) 14 (7) 0.003 0.021
Prior smoking, % (n) 27 (55) 42 (21) 0.039 0.590
Antihypertensive drugs, % (n) 83 (171) 58 (29) 0.004 0.119
Aspirin, % (n) 29 (59) 26 (13) 0.861 0.355
Statin, % (n) 39 (81) 2 (1) b0.001 0.001
Glomerular ﬁltration rate,
(mL/min)
69.8 ±
18.9
54.8 ±
20.8
b0.001 0.003
HDL-C, (mg/dL) 55 ± 14 44 ± 10 b0.001 0.763
LDL-C, (mg/dL) 114 ± 36 110 ± 39 0.495 0.571
Triglycerides, (mg/dL) 115 (65) 105 (55) 0.085 0.616
C-reactive protein, (mg/dL) 1.90 (2.38) 0.52 (1.09) b0.001 0.001
Systolic blood pressure, (mm Hg) 142 (25) 130 (40) 0.040 0.001
Diastolic blood pressure, (mm Hg) 73 (15) 80 (30) 0.009 0.001
Heart rate, (bpm) 73 (15) 70 (26) 0.436 0.001
a Analysis of covariance with adjustment for gender and age. HDL-C: High-density li-
poprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol. Normal data are pre-
sented as mean ± SD and skewed data as median and interquartile range (IQR).
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even after exclusion of 4 patients with SBP b 100 mm Hg (Table 5).
Indeed, the inverse association between HDL-C levels and STEMI seems
to be dose-dependent.
As shown in Table 3, gender, moderate to severe depressive
symptoms, prior and current smoking was associated with STEMI in
unadjusted models. After fully adjustments, all risk factors remained
signiﬁcantly related to STEMI, except for prior and current smoking.Table 2
Multivariable ordinal regressionmodels to assess the association between categorical var-
iables split in tertiles and STEMI in elderly participants.
Age OR(95% CI); p-value
1st tertile 2nd tertile 3rd tertile
≤82 years
n= 107
82–86 years
n= 70
≥86 years
n= 80
Model 1 Ref group 1.70(0.80–1.61); 0.168 1.32(0.62–2.81); 0.466
Model 2 Ref group 2.87(0.82–10.07); 0.100 1.81(0.54–6.15); 0.335
LDL-C 1st Tertile 2nd Tertile 3rd Tertile
≤96.92 mg/dL 96.92–127.83 mg/dL ≥127.83 mg/dL
n= 84 n= 85 n= 85
Model 1 Ref group 0.62(0.28–1.35); 0.227 0.86(0.41–1.79); 0.678
Model 2 Ref group 1.42(0.42–4.76); 0.568 1.25(0.40–3.96); 0.703
Triglycerides 1st Tertile 2nd Tertile 3rd Tertile
≤95.92 mg/dL 137–95.92 mg/dL ≥137 mg/dL
n= 84 n= 84 n= 86
Model 1 Ref group 0.81(0.39–1.69); 0.577 0.52(0.24–1.14); 0.104
Model 2 Ref group 0.55(0.14–2.07); 0.375 0.31(0.09–1.08); 0.066
HDL-C 3rd Tertile 2nd Tertile 1st Tertile
≥58 mg/dL 58-45 mg/dL ≤45 mg/dL
n= 87 n= 91 n= 76
Model 1 Ref group 2.98(1.02–8.67); 0.045 10.70(3.88–29.46); 0.001
Model 2 Ref group 5.83(1.16–29.16); 0.032 7.00(1.53–32.04); 0.012
Model 3 Ref group 3.14(10.7–9.22); 0.037 13.67(4.84–38.59); 0.001
3rd Tertile 2nd Tertile 1st Tertile
GFR ≥74.40 mL/min 58.42–74.40 mL/min ≤58.42 mL/min
n= 83 n= 83 n= 83
Model 1 Ref group 2.39(0.92–6.22); 0.073 4.41(1.78–10.95); 0.001
Model 2 Ref group 1.72(0.50–5.82); 0.386 4.37(1.30–14.69); 0.017
Model 3 Ref group 2.74(1.04–7.20); 0.041 4.90(1.95–12.33); 0.001
Model 1: Unadjusted;Model 2: Fully adjusted;Model 3: Fully adjusted, including CRP. OR:
Odds ratio; CI: Conﬁdence interval; HDL-C: High-density lipoprotein cholesterol; LDL-C:
Low-density lipoprotein cholesterol; GFR: Glomerular ﬁltration rate.3.3. Attributable risk
Table 4 showsAR for each signiﬁcant STEMI risk factors. According to
AR values,male gender, lowHDL-C level and lowHDL-C associatedwith
low GFR were the three strongest risk factors, followed by moderate to
severe depressive symptoms, current smoking, low GFR and prior
smoking.
Since both low HDL-C and low GFR were the main determinants of
the AR, we hypothesized that increased systemic inﬂammatory activity
would potentially mediate the association between these two factors
and STEMI. Plasma CRP was therefore included in the modeling in
order to verify its potential mediating effect between HDL-C or GFR
and STEMI risk (Table 2, model 3). HDL-C and GFR associations to
STEMI remained unchanged after adjustment for CRP.
4. Discussion
To the best of our knowledge, this is the ﬁrst case-control study
designed to investigate independent risk markers for STEMI among
very elderly individuals. Our ﬁndings indicate that, in this population,
STEMI is associated with: (i) male gender, (ii) low HDL-C levels,
(iii) moderate to severe depressive symptoms, (iv) low GFR, and
(v) smoking status. Of note, low GFR and/or low HDL-C underlies
N50% of the AR for these individuals.
Plasma LDL-C is among the main risk factors for atherosclerotic
disease in adults and young elders [13–15]. In contrast, this association
seems to become weaker or non-signiﬁcant among older patients [16,
17]. With regards to HDL-C, the strength of the association tends to
increase with aging [18,19]. Our present ﬁndings corroborate these
reports. We found that low HDL-C levels are singularly associated with
a 7-fold increase in STEMI risk while LDL-C and triglycerides levels
posed no impact. Interestingly, 73% of population-attributed risk may be
related to low HDL-C levels, deeming it the most impactful risk factor of
STEMI in the very elderly.
A broad spectrum of mechanisms paves the existence of a mutual
association between cardiovascular and renal diseases. In fact, renal
dysfunction is both cause and consequence of atherosclerosis [20]. As
one may expect, at 80 years or older, the residual GFR is decreased
due to its inherent lifetime decline [21]. Nevertheless, we found that
54% of the cases and 31% of the controls had GFR bellow the expected
value for age and gender [22], thus indicating that the accelerated
decline in renal function may have contributed to STEMI. In general,Table 3
Multivariable binary logistic regression models to assess the association between binary
variables and STEMI in elderly participants.
Diabetes mellitus OR(95% CI); p-value
Model 1 0.631(0.277–1.436); 0.272
Model 2 0.302(0.081–1.131); 0.075
Hypertension OR(95% CI); p-value
Model 1 0.642 (0.326–1.261); 0.198
Model 2 0.601(0.182–1.990); 0.405
Gender: male OR(95% CI); p-value
Model 1 12.08(5.82–25.08); 0.001
Model 2 12.08(3.75–38.97); 0.001
Mild depressive symptoms OR (95% CI); p-value
Model 1 0.93(0.33–2.61); 0.884
Model 2 1.43(0.35–5.83); 0.615
Moderate to severe depressive symptoms OR(95% CI); p-value
Model 1 10.00(2.82–35.50); 0.001
Model 2 38.20(4.81–303.48); 0.001
Current smoking OR(95% CI); p-value
Model 1 6.58(1.99–21.70); 0.002
Model 2 1.52(0.17–13.33); 0.706
Ex smoking OR(95% CI); p-value
Model 1 2.00(1.05–3.80); 0.034
Model 2 1.36(0.47–3.87); 0.570
Model 1: Unadjusted; Model 2: Fully adjusted. OR: Odds ratio; CI: Conﬁdence interval.
Table 4
Attributable risk of independent risk markers.
Characteristics Attributable
Risk (95% CI)
Pr N |Z|
Gender: Male 85.47% (81.08–88.20) b0.001
Depressive symptoms: moderate to severe 75.00% (58.33–82.14) b0.001
Current smoking 69.91% (42.34–79.65) 0.004
Prior smoking 42.02% (8.85–57.48) 0.023
Low GFR 68.18% (50.42–76.57) b0.001
Low HDL-C 85.44% (79.82–88-61) b0.001
Low HDL-C and low GFR 83.83% (74.75–87.89) b0.001
Low HDL-C or low GFR 72.34% (61.59–78.38) b0.001
Low GFR: ≤58.42 mL/min; Low HDL-C: ≤45 mg/dL. 3rd versus 1st tertiles were tested.
HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol;
GFR: Glomerular ﬁltration rate.
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short-term mortality after MI [23,24]. Our ﬁndings corroborate this by
showing that even a mild to moderate reduction of GFR may increase
STEMI risk in N4-fold among very old individuals. Such degree of renal
dysfunction may explain up to 52% of the STEMI risk of this aged
population. Surprisingly, low GFR and low HDL-C were not additive in
their impact on STEMI risk, suggesting a common mechanism of inter-
action. Although plausible, increased systemic inﬂammatory activity
does not seem to be one of the mediators for these interactions since
the inclusion of plasma CRP in the models did not change the associa-
tions between GFR or HDL-C and STEMI.
Throughout life, the impact of hypertension and diabetes on MI risk
appears to wean and eventually ceases to exist at 85 years of age [25].
Consistently, our ﬁndings support the weakening of the impact of
diabetes and hypertension on STEMI risk. This lack of association in
the very elderly may be explained by differences in the pathogenesis
of atherosclerosis between the young and the very old. For example,
in contrast to younger individuals, the onset of diabetes in the elderly
is more likely to result from the failure of beta cells because of cellular
senescence of pancreatic islets rather than from increased resistance
to insulin [26]. Likewise, in contrast to the young, the increase of
blood pressure is frequently related to the development of vascular
stiffening in the elderly [27].
Despite the reduction in smoking prevalence with aging [13,15], our
results demonstrate its persistent relevance on the risk of MI among the
very elderly. In opposition to prior reports of risk cessation around
6 years after smoke interruption [28], the present study indicates that
the impact of smoking habit on atherogenesis may persist for a longer
period of time after its cessation. According to our data, the smoking-
related risk was persistent around 20 years after interruption and
former smoking was responsible for AR of 69.91%. As the smoking
abstention time was higher in controls than in cases, one may infer
that the risk attenuation is a continuous and slow process.
The presence andmagnitude of depressive symptoms has long been
associated with the risk of MI [29]. From a pathophysiological point
of view, this association may be due to direct effects, i.e., increased
inﬂammatory activity and thrombogenesis, and indirect, such as physicalTable 5
Multivariable ordinal logistic regression models to assess the association between GFR
split in tertiles and STEMI in elderly, excluding participants with SBP b 100 mm Hg.
OR (95% CI); p-value
3rd tertile 2nd tertile 1st tertile
GFR ≥74.83 mL/min
n= 82
58.59–74.83 mL/min
n= 82
≤58.59 mL/min
n= 81
Model 1 Ref group 2.83 (1.04–7.72); 0.041 4.43 (1.68–11.68); 0.003
Model 2 Ref group 2.65 (0.74–9,54); 0.135 5.20 (1.43–18.90); 0.012
Model 3 Ref group 3.21 (1.17–8.85); 0.024 4.89 (1.83–13.03); 0.002
Model 1: Unadjusted;Model 2: Fully adjusted;Model 3: Fully adjusted, including CRP. OR:
Odds ratio; CI: Conﬁdence interval; GFR: Glomerular ﬁltration rate.inactivity, smoking and poor adherence to the control of risk factors [30].
Some differences between young adults and the very elderly, however,
have prevented the extrapolation of this concept. For example, in
the very elderly, age-related biological and behavioral changes
such as immunosenescence, increased thrombogenesis and inability
to change habits would potentially undermine this association. In
addition, although the prevalence of depressive symptoms increases
with age, the psychobiological constructs that favor such manifestation
is progressively changed with aging [31]. Our study demonstrates that
despite the above-mentioned changes, moderate to severe depressive
symptoms may account for 75% of STEMI AR.
In all ranges of age, gender has been consistently proven to play a
marked role in atherosclerotic burden and cardiovascular risk. Unde-
niably, men are more prone to manifest ischemic heart disease than
women, at any given age, lagging forward by approximately 10 years [32].
In our study, although aging over 80 years did not signiﬁcantly inﬂuenced
STEMI risk, male gender favors a 12-fold increase in risk.
Our study has some limitations that must be discussed. Mainly, the
enrollment and, by this way, the sample size was limited by the inclu-
sion criteria of the cases, e.g. admission in the ﬁrst 24 h from the onset
of STEMI symptoms. This criterion was decided based on these three
aspects: (i) to select individuals at undeniable high risk, (ii) to have
plasma lipid proﬁle obtained before the metabolic change induced by
MI, and (iii) to avoid selection bias due to the high mortality of STEMI
in this age group. This limitationmay favor an over- or underestimation
of the magnitude of the associations and may also inﬂuence the lack
of statistical signiﬁcance in some of the analyses. Nevertheless, the
uniqueness of the data and its consistency with age-related biological
processes involved in atherosclerotic disease make it relevant and
plausible.
4.1. Conclusions
In conclusion, this is the ﬁrst case–control study carried out with
very elderly participants that aimed to identify independent risk
markers for STEMI. Our ﬁndings indicate that reduced levels of HDL-C
and GFR are the most frequent and strongest risk markers in this age
group.
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